Foreign Travel Advice - UK

Omjjara licensed for anaemic myelofibrosis patients to treat the symptoms of their disease

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (30 January 2024) approved the medicine momelotinib (Omjjara) to treat the symptoms experienced by adult myelofibrosis patients who have moderate or se…

Read the original advice at Foreign Travel Advice (UK)

Related Articles

Back to top button